Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: OptimizeRx Corporation, 3 years.
OptimizeRx Corporation
Director
BioVie Inc.
Director
Halozyme Therapeutics Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
OptimizeRx Corporation June 9, 202681.6%
-
OptimizeRx Corporation June 11, 202563.5%
-
OptimizeRx Corporation June 5, 202476.4%
-
OptimizeRx Corporation June 7, 202359.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 9, 2026 | OptimizeRx Corporation | Grant or award | +34,517 | — | — |
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +3,796 | — | — |
| Jan 2, 2026 | Halozyme Therapeutics Inc. | Grant or award | +889 | — | — |
| Jun 11, 2025 | OptimizeRx Corporation | Grant or award | +9,868 | — | — |
| Mar 14, 2025 | OptimizeRx Corporation | Open-market purchase | +321,408 | $7.60 | $2,442,701 |
| Jun 7, 2024 | OptimizeRx Corporation | Grant or award | +13,286 | — | — |
| Jun 5, 2024 | OptimizeRx Corporation | Option exercise | +10,061 | — | — |
| Jun 7, 2023 | OptimizeRx Corporation | Option exercise | +4,637 | — | — |
| Mar 30, 2023 | OptimizeRx Corporation | Option exercise | +657 | — | — |
| Dec 30, 2022 | OptimizeRx Corporation | Option exercise | +409 | — | — |
| Nov 23, 2022 | BioVie Inc. | Grant or award | +43,578 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.